Frank Vinluan / medcitynews - Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024. The post A Cancer Driven by Ultra-Rare Mutation …
AI Summary: The FDA approved zenocutuzumab‑zbco for NRG1‑fusion–positive cholangiocarcinoma, delivering the first cleared therapy for cancers driven by this ultra‑rare genomic alteration. Trial data showed meaningful responses in heavily pretreated patients, prompting regulators to greenlight a precision option that offers targeted benefit where none existed — a small‑population win for genomic oncology.
medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.
AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.
livescience - Archaeologists discovered the 20-karat-gold dental wire in the lower jaw of a middle-aged man who lived around 500 years ago in Scotland.
AI Summary: Archaeologists uncovered what appears to be the earliest known gold dental bridge in Scotland, dating roughly four to five centuries ago and likely fitted with a faux tooth. The discovery sheds light on historic dental practice, craftsmanship and status signaling—proof that vanity and dental innovation are nothing new.
Christina Jewett / nytimes - Though illicit e-cigarettes have flooded in from China, the new policy could allow major tobacco companies to sell from prime shelf space at thousands of stores.
AI Summary: Facing mounting pressure, the FDA has signaled authorization of fruit‑flavored vaping products for adults, a regulatory shift framed as adult access and harm reduction. Public‑health experts warn the move risks increasing youth appeal and reignites debate over flavors, enforcement, and whether potential population‑level tradeoffs were adequately considered.

StackHealth RSS
StackHealth Time Machine
More StackHealth
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.